Recently, ZOLL Medical Corporation (ZOLL) announced that the U.S. Food and Drug Administration (FDA) approved the marketing of its E series defibrillators equipped with carbon monoxide (CO) monitoring. The new model of the ZOLL E series monitor/defibrillator is available for shipment with immediate effect.
 
The presence of CO monitoring in the new model is an impressive feature. It will protect firefighters, civilians and treat patients poisoned by CO immediately. If someone is continuously exposed to the gas then his heart and brain are liable to be affected in the long term. Furthermore, a solitary severe case of CO poisoning almost doubles the risk of premature demise.
 
People poisoned by this gas often display flu-like symptoms. However, it is also possible that people poisoned by this “silent killer” do not display any symptoms. Undetected, untreated episodes of CO poisoning can have very dangerous consequences and may even prove fatal in some cases.
 
The integration of the ZOLL product with Masimo’s (MASI) CO-Oximetry allows rescuers to diagnose CO poisoning easily and accurately. The early detection of the poisoning and the consequent treatment significantly reduce immediate and long-term health risks.
 
Headquartered in Chelmsford, Massachusetts, and founded in 1980, ZOLL designs, manufactures, markets and sells non-invasive resuscitation devices and related software solutions both in the U.S. and overseas.
 
We are pleased with the company’s wide range of products and significant international presence. ZOLL has made multiple acquisitions in the past that have aided growth. The company is looking for more such opportunities. Consequently we have an Outperform rating on ZOLL Medical.
Read the full analyst report on “ZOLL”
Read the full analyst report on “MASI”
Zacks Investment Research